Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collagen type II, particularly in its undenatured (native) form like UC-II, is a protein-based nutraceutical derived from sources such as chicken sternum cartilage. It is primarily used for the management of joint-related conditions like osteoarthritis and rheumatoid arthritis. [1, 5, 11] Unlike hydrolyzed collagen, which provides structural building blocks for cartilage, undenatured type II collagen operates through an immune-mediated mechanism known as 'oral tolerance'. [1, 2, 8] When taken orally in low doses (typically 40 mg/day), it interacts with the gut-associated lymphoid tissue (GALT), leading to the generation of regulatory T-cells. [1, 6] These specialized immune cells then help to suppress the body's inflammatory attack on its own joint cartilage, thereby reducing pain and inflammation. [1, 7] Clinical studies, including Phase III trials, have demonstrated its effectiveness and safety in treating rheumatoid arthritis, showing it to be a well-tolerated alternative, though generally less potent than conventional drugs like methotrexate. It is marketed as a dietary supplement. [11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on collagen type ii.